|
« Bakersfield Propecia Lawyer California Attorneys |
Main
| Stockton Propecia Lawyer California Attorneys »
|
 |
|
FDA Announces New Scrutiny on Blood Clot Risk From Birth Control Pills With Drospirenone
|
Two recently-published studies on YAZ and other birth control pills containing Drospirenone have caught the attention of the U.S. Food and Drug Administration. The FDA announced yesterday that it is aware of the studies, which conclude that women using birth control pills containing
Drospirenone have a 2-to-3 times greater risk of developing blood clots compared to women using other forms of birth control.
Although the most recent studies, along with several older ones, conclude there is a significantly greater risk of blood clots from Drospirenone, a few others have found no increased risk. Prompted by the most recent studies, the FDA announced it “will look at all currently available information to fully assess the risks and benefits of drospirenone-containing birth control pills.”
Drospirenone is a type of synthetic progestin used in
YAZ and Yasmin oral contraceptives. Drospirenone is unique because it is a potassium-sparing diuretic. It’s diuretic properties mean that its use leads to less weight gain than other birth control pills. However, it also means women using it can develop abnormally high potassium levels, which itself can cause a dangerous condition called hyperkalemia.
Yasmin is also sold under the generic names Zarah,
Ocella and Zyeda. Generic forms of YAZ are Gianvi and Loryna. Both YAZ and Yasmin contain the same amount of
Drospirenone. They differ in their dosing schedule because of the amount of ethinyl estradiol (estrogen) they contain.
The FDA’s announcement states that it will continue to communicate any new safety information to the public as it becomes available. We, in turn, will pass on any further announcements from the FDA.
The complete announcement from the FDA may be found HERE.
|
|
|
|
|
|
|
Posted By DeCarli Law on
June 01, 2011 08:15 am |
Permalink
|
|